Last Updated: November 16, 2026

Investigational Drug Information for Telotristat ethyl

« Back to Dashboard


What is the drug development status for Telotristat ethyl?

Telotristat ethyl is an investigational drug.

There have been 9 clinical trials for Telotristat ethyl. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2020.

The most common disease conditions in clinical trials are Neuroendocrine Tumors, Carcinoid Tumor, and Malignant Carcinoid Syndrome. The leading clinical trial sponsors are Lexicon Pharmaceuticals, TerSera Therapeutics LLC, and M.D. Anderson Cancer Center.

There are thirty US patents protecting this investigational drug and one hundred and twenty-four international patents.

Recent Clinical Trials for Telotristat ethyl
TitleSponsorPhase
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine TumorM.D. Anderson Cancer CenterPhase 3
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat EthylTerSera Therapeutics LLCPhase 2
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat EthylBig Ten Cancer Research ConsortiumPhase 2

See all Telotristat ethyl clinical trials

Clinical Trial Summary for Telotristat ethyl

Top disease conditions for Telotristat ethyl
Top clinical trial sponsors for Telotristat ethyl

See all Telotristat ethyl clinical trials

US Patents for Telotristat ethyl

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Telotristat ethyl ⤷  Start Trial Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase ACTELION PHARMACEUTICALS LTD (Allschwil, CH) ⤷  Start Trial
Telotristat ethyl ⤷  Start Trial Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (Berlin, DE) FORSCHUNGSVERBUND BERLIN E.V. (Berlin, DE) ⤷  Start Trial
Telotristat ethyl ⤷  Start Trial SSTR-targeted conjugates and particles and formulations thereof TVA ABC LLC ⤷  Start Trial
Telotristat ethyl ⤷  Start Trial SSTR-targeted conjugates and particles and formulations thereof TVA ABC LLC ⤷  Start Trial
Telotristat ethyl ⤷  Start Trial Calcium lactate compositions and methods of use Metimedi Pharmaceuticals Co Ltd ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Telotristat ethyl

Drugname Country Document Number Estimated Expiration Related US Patent
Telotristat ethyl Canada CA2927121 2033-11-19 ⤷  Start Trial
Telotristat ethyl China CN105745211 2033-11-19 ⤷  Start Trial
Telotristat ethyl European Patent Office EP3071567 2033-11-19 ⤷  Start Trial
Telotristat ethyl Spain ES2650921 2033-11-19 ⤷  Start Trial
Telotristat ethyl Japan JP2016537378 2033-11-19 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Telotristat Ethyl Development Update and Market Projection

Last updated: September 1, 2026

Telotristat ethyl is a commercial orphan drug, not an early-stage development candidate. Marketed as Xermelo by Ipsen, it is approved in the United States and European Union for carcinoid syndrome diarrhea that is inadequately controlled by somatostatin analog therapy. The drug has a differentiated mechanism, limited direct competition, and a small addressable population. Its principal commercial risks are low patient volume, dependence on specialist diagnosis, reimbursement constraints, and eventual generic entry after orphan and patent protections expire.

The base-case outlook is a stable niche product with modest growth through 2028. A reasonable global net-sales range is approximately $80 million to $115 million annually during that period, subject to patient identification, pricing, and generic timing. The upside case depends on broader use in carcinoid syndrome and stronger penetration outside the United States. Large label expansions are not currently central to the investment case.

What is telotristat ethyl and how does it work?

Telotristat ethyl is an orally administered prodrug of telotristat. Telotristat inhibits tryptophan hydroxylase 1, or TPH1, the rate-limiting enzyme in peripheral serotonin synthesis. Carcinoid tumors can produce excessive serotonin, causing diarrhea and other carcinoid syndrome symptoms. By reducing peripheral serotonin production, telotristat reduces diarrhea frequency without directly suppressing tumor growth.

The drug is generally used with a somatostatin analog such as octreotide or lanreotide. It is not a replacement for antitumor therapy or a treatment for all symptoms associated with carcinoid syndrome.

Attribute Telotristat ethyl
Brand Xermelo
Active drug Telotristat
Drug class Peripheral TPH1 inhibitor
Developer Lexicon Pharmaceuticals
Commercial partner Ipsen
Initial U.S. approval March 6, 2017
U.S. indication Carcinoid syndrome diarrhea inadequately controlled by somatostatin analog therapy
Standard adult dose 250 mg orally three times daily with food
Primary treatment setting Gastroenterology, oncology, neuroendocrine tumor care
Main competitor Somatostatin analog therapy, principally octreotide and lanreotide
Regulatory status Approved commercial product

The FDA approval was based primarily on the TELESTAR study, which showed a statistically significant reduction in daily bowel movements compared with placebo in patients with carcinoid syndrome diarrhea receiving somatostatin analog therapy. The TELECAST study supplied additional evidence in patients with less frequent baseline bowel movements and supported the broader clinical profile of the product. (Kulke et al., 2017; FDA, 2017)

What is the current development status of telotristat ethyl?

Telotristat ethyl completed its central development program and remains in the commercial lifecycle-management phase. The major development milestones were:

Date Milestone
2010s Lexicon advances telotristat into clinical development for carcinoid syndrome
2014 Lexicon licenses commercialization rights outside Japan to Ipsen
February 2017 FDA advisory and regulatory review process completed
March 6, 2017 U.S. FDA approves Xermelo
September 2017 European Commission authorizes Xermelo in the EU
2017 onward Commercial launch, postmarketing surveillance and real-world use
2020s Product remains focused on carcinoid syndrome diarrhea rather than a broad new indication

Ipsen’s commercial strategy has centered on specialist promotion and integration with its broader oncology portfolio, including therapies used in neuroendocrine tumors. The product benefits from commercial adjacency to somatostatin analogs and neuroendocrine tumor specialists, although telotristat ethyl is not a tumor-directed therapy.

No major approved indication expansion has materially changed the product’s market size. Development activity has primarily involved clinical use, long-term safety, treatment sequencing, and observational evidence rather than a new therapeutic franchise.

What FDA-approved indication does Xermelo have?

Xermelo is approved for adults with carcinoid syndrome diarrhea inadequately controlled by short-acting octreotide. The approved dosage is 250 mg three times daily with food. The label permits a lower 250 mg twice-daily dose when tolerability or safety considerations require dose reduction. (FDA, 2024)

The FDA label identifies constipation and increased hepatic enzymes among important adverse reactions. The product is also subject to gastrointestinal tolerability and liver-monitoring considerations. Its use is concentrated in patients with persistent diarrhea despite somatostatin analog treatment.

The product’s clinical value is highest in patients who continue to experience frequent bowel movements despite standard therapy. That positioning limits the eligible population but supports use as an add-on treatment rather than requiring displacement of first-line somatostatin analogs.

How large is the telotristat ethyl market?

The addressable market is small but commercially defensible because carcinoid syndrome is associated with a relatively limited neuroendocrine tumor population and diagnosis is concentrated in specialist centers.

Public epidemiology estimates vary because prevalence depends on tumor site, metastatic status, serotonin secretion, and diagnostic coding. A practical market model separates the population into four groups:

  1. Patients with neuroendocrine tumors but no clinically significant carcinoid syndrome.
  2. Patients with carcinoid syndrome controlled by somatostatin analog therapy.
  3. Patients with persistent diarrhea despite somatostatin analog therapy.
  4. Patients eligible for, prescribed, and reimbursed for telotristat ethyl.

The third group is the core clinical market. The fourth group is the commercial market and is materially smaller.

Estimated market funnel

Market stage Approximate commercial implication
Global neuroendocrine tumor population Large and growing, but mostly outside the product’s indication
Patients with carcinoid syndrome Minority of neuroendocrine tumor patients
Patients with uncontrolled diarrhea on somatostatin analogs Narrow target population
Treated Xermelo patients Small orphan-drug population
Annual global sales potential More consistent with a specialty orphan product than a mass-market drug

The main growth drivers are improved diagnosis of neuroendocrine tumors, longer survival, greater use of specialist centers, and increased recognition of persistent diarrhea as a treatable condition. The main constraints are generic somatostatin analog use, underdiagnosis, treatment discontinuation, reimbursement review, and competition from symptom-management approaches.

What are the telotristat ethyl market projections through 2028?

A scenario-based forecast is more appropriate than a single-point estimate because publicly available product-level sales disclosures are limited and the treated population is small.

Telotristat ethyl revenue scenarios

Year Downside case Base case Upside case
2024 $70 million $85 million $100 million
2025 $68 million $88 million $105 million
2026 $65 million $92 million $110 million
2027 $60 million $96 million $115 million
2028 $50 million $100 million $120 million

These figures are analytical estimates for global net sales, not Ipsen guidance. The base case assumes low-single-digit volume growth, broadly stable specialty-drug pricing, continued use with somatostatin analogs, and no major generic launch before the end of the forecast period.

The downside case assumes weak patient growth and earlier generic or authorized-generic pressure in one or more markets. The upside case assumes stronger diagnosis, higher treatment persistence, and continued regulatory protection in Europe.

The product is unlikely to become a major revenue contributor to Ipsen. Its strategic value is greater than its absolute revenue contribution because it strengthens Ipsen’s position in rare neuroendocrine diseases and provides a recurring oral therapy that complements injectable treatments.

When does telotristat ethyl lose exclusivity?

U.S. regulatory exclusivity has already declined materially. The FDA approved Xermelo on March 6, 2017. Its orphan-drug exclusivity period generally ran for seven years, through March 6, 2024. New chemical entity exclusivity generally ran for five years, through 2022. Orphan exclusivity does not prevent all patent-based challenges, but it prevents approval of the same drug for the same indication during the orphan period unless statutory exceptions apply.

Patent exclusivity may extend beyond regulatory exclusivity. The effective generic-entry date depends on the expiration and enforceability of listed patents, any pediatric extension, patent-term adjustment, patent-term extension, litigation, and the scope of an applicant’s Paragraph IV certification.

Protection Approximate U.S. timing Commercial effect
New chemical entity exclusivity Through approximately 2022 Delayed certain ANDA approvals
Orphan-drug exclusivity Through approximately March 2024 Blocked approval of the same drug for the protected indication
Orange Book patents Potentially beyond 2024 May delay or trigger patent litigation
EU orphan market exclusivity Generally approximately 10 years from EU authorization Can extend protection into the late 2020s
Patent-term adjustments or pediatric extensions Patent-specific Could affect final generic-entry timing

An orphan exclusivity expiration does not mean immediate generic launch. A generic applicant must still address Orange Book-listed patents and satisfy bioequivalence, formulation, manufacturing, labeling, and regulatory requirements.

What patents protect telotristat ethyl?

The patent estate is expected to include claims directed to the active compound, pharmaceutical compositions, formulations, methods of reducing serotonin or treating carcinoid syndrome, and manufacturing or synthetic processes. The commercial strength of the estate depends less on the number of patents than on whether valid claims cover the approved product and its principal use.

Potential protection categories include:

Protection category Relevance to Xermelo
Compound claims Protect telotristat or related chemical entities
Prodrug claims Protect telotristat ethyl as the orally administered prodrug
Composition claims Cover dosage forms and pharmaceutical compositions
Method-of-use claims Cover treatment of carcinoid syndrome diarrhea
Manufacturing claims Create process barriers but may be avoidable by alternative synthesis
Salt, crystalline or formulation claims May delay substitution if narrowly drafted and clinically relevant

The strongest potential barriers are compound or prodrug claims that remain enforceable after regulatory exclusivity ends, followed by formulation or method-of-use claims that map closely to the approved label. Process patents usually create a weaker barrier because a generic manufacturer may design around them.

The Orange Book should be reviewed for the current patent list and expiration dates before making a launch or litigation decision. Patent listings can change, and the relevant risk is determined by the patents listed at the time of an ANDA filing and the claims asserted in litigation.

Are there Paragraph IV challenges to Xermelo?

A Paragraph IV challenge is a plausible post-exclusivity pathway because telotristat ethyl is an oral small molecule with an approved indication and a potentially limited manufacturing burden. Public evidence of a significant, commercially consequential Paragraph IV challenge has not established a defined generic launch date through the available regulatory record.

A generic applicant could file an ANDA using one of several certification strategies:

  • Paragraph III certification, agreeing to wait until listed patents expire.
  • Paragraph IV certification, alleging that listed patents are invalid, unenforceable or not infringed.
  • Section viii statement, carving out a patented method of use from the proposed label.

The section viii route could be difficult if the core commercial use is closely aligned with the approved indication and the listed method-of-use claims cover treatment of carcinoid syndrome diarrhea. The commercial attractiveness of a Paragraph IV filing is reduced by the small patient population, specialist prescriber base, and limited total revenue opportunity.

What is the Orange Book status of Xermelo?

Xermelo is an FDA-approved prescription drug and should be evaluated through the FDA Orange Book for current listed patents, use codes, exclusivity codes and reference-listed-drug status. The Orange Book is the controlling source for current U.S. listing information.

The relevant diligence questions are:

  1. Which patents are currently listed for Xermelo?
  2. What are the expiration dates after any patent-term adjustment?
  3. Are the listed claims directed to the compound, formulation or method of use?
  4. Can a generic applicant use a section viii carve-out?
  5. Has any ANDA applicant filed a Paragraph IV certification?
  6. Has Ipsen or an affiliated patent holder initiated Hatch-Waxman litigation?

No broad generic substitution should be assumed solely because U.S. orphan exclusivity expired in 2024. Regulatory exclusivity and patent exclusivity operate separately.

How strong is the telotristat ethyl patent estate?

The estate is commercially moderate rather than impenetrable.

Strengths include:

  • A differentiated active mechanism.
  • An orphan indication with limited direct competition.
  • Potential compound, prodrug and method-of-use coverage.
  • Specialist prescribing and high switching friction.
  • Regulatory and manufacturing experience held by the incumbent.

Weaknesses include:

  • Small-molecule chemistry that is generally accessible to generic manufacturers.
  • A narrow indication and limited revenue pool.
  • The expiration of U.S. regulatory exclusivity.
  • Potential use of section viii labeling strategies.
  • Limited value in manufacturing patents if alternative processes are available.

The likely outcome is a delayed but not permanently blocked generic threat. Patent litigation could extend the branded period, but the economic incentive for a generic challenger will depend on expected sales, litigation costs, the number of competitors, and the ability to obtain reimbursement.

What generic launch scenarios exist for telotristat ethyl?

Scenario 1: No near-term generic filing

Ipsen retains the market through the late 2020s because the remaining patent estate is not challenged or because the market is too small to attract an early challenger. This supports the base-case forecast.

Scenario 2: Single generic entrant

One applicant launches after patent expiry or settles with Ipsen. Price erosion is moderate because the product is prescribed by specialists and the treated population is limited. Net sales could decline by 20% to 40% over two years.

Scenario 3: Multiple generic entrants

Several ANDA approvals produce more conventional small-molecule price erosion. Sales could fall by 50% to 80% over two to three years, depending on payer substitution and wholesaler stocking.

Scenario 4: Authorized generic or settlement

Ipsen could preserve some economics through an authorized generic, license arrangement or settlement that delays independent entry. Such an arrangement would reduce abrupt revenue loss but could also accelerate price competition.

Which companies are commercializing or challenging telotristat ethyl?

Ipsen is the principal commercial company for Xermelo outside territories subject to separate arrangements. Lexicon discovered and developed the drug and licensed commercialization rights to Ipsen. The product’s competitive set is driven less by another TPH1 inhibitor than by established carcinoid syndrome treatments.

Company or therapy Competitive position
Ipsen, Xermelo Approved add-on treatment for refractory carcinoid syndrome diarrhea
Lexicon Pharmaceuticals Originator and development partner
Novartis, Sandostatin LAR Standard somatostatin analog and foundational therapy
Ipsen, Somatuline Somatostatin analog used in neuroendocrine tumor care
Generic octreotide Lower-cost alternative to branded somatostatin analog therapy
Supportive antidiarrheal therapy Common symptomatic management option
Future generic telotristat Main post-exclusivity substitution risk

No approved biosimilar can replace telotristat ethyl because it is a chemically synthesized small molecule, not a biologic. The relevant competitive threat is generic substitution, not biosimilar interchangeability.

What licensing deal affects telotristat ethyl?

Lexicon granted Ipsen rights to develop and commercialize telotristat outside Japan under a 2014 agreement. The transaction gave Ipsen commercial responsibility and strengthened its rare-disease and neuroendocrine oncology portfolio. Lexicon retained economic participation through milestone and royalty arrangements described in its corporate filings. (Lexicon Pharmaceuticals, 2014)

The agreement is commercially important because it separates originator ownership and development history from global commercial execution. Ipsen’s sales infrastructure and oncology relationships are central to market access, while Lexicon remains associated with the underlying discovery and development program.

What litigation and settlement risks affect Xermelo?

The primary litigation risk is Hatch-Waxman litigation following a Paragraph IV certification. A filing would require review of the listed patents, asserted claims, use codes and the proposed generic label. A timely patent suit could trigger a 30-month stay of ANDA approval under U.S. law, subject to statutory conditions and court action.

Other potential disputes include:

  • Patent ownership or inventorship claims.
  • Royalty or milestone disputes between Lexicon and Ipsen.
  • Manufacturing-process challenges.
  • Labeling disputes involving the refractory diarrhea population.
  • Regulatory disputes over therapeutic equivalence or substitutability.

A settlement could delay generic entry while allowing a future launch date. The value of such a settlement is constrained by the product’s modest market size.

How does telotristat ethyl compare with competing carcinoid syndrome treatments?

Telotristat ethyl has a narrower indication than somatostatin analogs but addresses a specific residual symptom.

Factor Telotristat ethyl Somatostatin analogs
Primary role Add-on treatment for persistent diarrhea Core treatment for hormone secretion and tumor-related symptoms
Administration Oral, three times daily Usually injectable, including long-acting formulations
Mechanism Reduces peripheral serotonin synthesis Suppresses hormone secretion and receptor-mediated signaling
Tumor control Does not directly control tumor growth Used in neuroendocrine tumor management
Main advantage Oral treatment targeted to refractory diarrhea Broad clinical role and established use
Main limitation Narrow indication and dosing burden Injection burden and incomplete diarrhea control in some patients

Telotristat’s strongest commercial positioning is as a complementary treatment. It is unlikely to replace somatostatin analog therapy in the majority of patients.

What is the investment outlook for telotristat ethyl?

The commercial profile is defensive but limited.

Revenue exposure is modest relative to Ipsen’s major products. The product can generate durable orphan-drug cash flow if Ipsen retains pricing and prevents rapid generic substitution. Growth is more likely to come from patient identification and treatment persistence than from a major increase in price or a new indication.

Key valuation variables are:

  • Number of treated patients.
  • Net price per patient per year.
  • U.S. and European reimbursement.
  • Duration of therapy.
  • Timing of generic filings.
  • Patent validity and enforceability.
  • Share of patients controlled by somatostatin analog therapy alone.
  • Competitive impact from improved tumor-directed treatment.

A reasonable base case is stable to low-single-digit annual growth through 2028, followed by a sharper decline if a generic launches. The product does not currently support a high-growth biotech valuation thesis, but it can support recurring specialty-pharma revenue and strategic positioning in neuroendocrine disease.

Key takeaways

  • Telotristat ethyl, marketed as Xermelo, is an approved orphan drug for carcinoid syndrome diarrhea inadequately controlled by somatostatin analogs.
  • Its mechanism is peripheral TPH1 inhibition, which reduces serotonin production.
  • The central development program is complete; current activity is commercial lifecycle management and postmarketing evidence.
  • U.S. orphan exclusivity expired in March 2024, while patent and non-U.S. protections may continue later.
  • The product has no biosimilar risk because it is a small molecule.
  • Generic risk is real but moderated by a small specialist market and limited revenue opportunity.
  • A base-case global net-sales forecast is approximately $85 million in 2024 rising to about $100 million by 2028.
  • The principal downside is an early generic launch followed by rapid price erosion.
  • Ipsen is the commercial owner, while Lexicon is the originator and licensing partner.
  • The patent estate is commercially meaningful but unlikely to create permanent protection against generic entry.

FAQs about telotristat ethyl

Is telotristat ethyl a chemotherapy drug?

No. Telotristat ethyl is a targeted serotonin-synthesis inhibitor used to control carcinoid syndrome diarrhea. It does not function as cytotoxic chemotherapy and does not directly treat tumor growth.

Can telotristat ethyl be used without octreotide or lanreotide?

The approved U.S. use is as an add-on to short-acting octreotide in patients with inadequate control of carcinoid syndrome diarrhea. Use outside the approved treatment framework depends on clinical judgment and local labeling.

Is Xermelo administered once daily?

No. The standard FDA-labeled dose is 250 mg three times daily with food. Dose reduction may be used when clinically appropriate.

Will a telotristat generic be automatically substitutable for Xermelo?

Substitution depends on FDA approval as therapeutically equivalent, state pharmacy law, payer policy and the generic’s approved labeling. A generic approval alone does not guarantee automatic substitution in every jurisdiction.

Does telotristat ethyl have potential in ulcerative colitis or irritable bowel syndrome?

The approved commercial program is focused on carcinoid syndrome diarrhea. A major value increase from inflammatory bowel disease or irritable bowel syndrome would require new clinical evidence and regulatory approval; it is not part of the current established product thesis.

References

  1. European Medicines Agency. (2017). Xermelo: EPAR - product information. https://www.ema.europa.eu/

  2. Food and Drug Administration. (2017). FDA approves Xermelo for carcinoid syndrome diarrhea. U.S. Department of Health and Human Services. https://www.fda.gov/

  3. Food and Drug Administration. (2024). Xermelo (telotristat ethyl) prescribing information. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/

  4. Ipsen. (2024). Universal registration document and annual financial report 2023. https://www.ipsen.com/

  5. Kulke, M. H., Hörsch, D., Caplin, M. E., Anthony, L. B., Bergsland, E., Öberg, K., Welin, S., Warner, R. R. P., Lombard-Bohas, C., Kunz, P. L., Grande, E., Valle, J. W., Denecke, T., Ferone, D., Caplin, M. E., & TELESTAR investigators. (2017). Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. New England Journal of Medicine, 376(12), 1116-1127. https://doi.org/10.1056/NEJMoa1615837

  6. Lexicon Pharmaceuticals, Inc. (2014). Lexicon Pharmaceuticals and Ipsen enter into licensing agreement for telotristat etiprate. https://www.lexpharma.com/

  7. U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: Telotristat ethyl clinical studies. https://clinicaltrials.gov/

  8. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.